The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
Open accessAbstract
The development of malignant disease might be seen as a failure of immune surveillance. However, not all tumors are naturally immunogenic, and even among those that are immunogenic, the uncontrolled rapid growth of a tumor may sometimes out-run a robust immune response. Nevertheless, recent evidence suggests that mechanisms of tolerance that normally exist to prevent autoimmune disease may also preclude the development of an adequate antitumor response and that tumors themselves have the ability to thwart the development of effective immune responses against their antigens. A major challenge has been to develop approaches to breaking this tolerance in tumor-bearing hosts, and recent advances in our understanding of antigen presentation and tolerance have led to some promising strategies. An alternative approach is to use T cells from nontumor-bearing, allogeneic hosts in the form of lymphocyte infusions, with or without hematopoietic cell transplantation. Immunotherapy may occur in this setting via the response of nontolerant, tumor antigen-specific T cells from nontumor-bearing hosts or via the powerful destructive effect of an alloresponse directed against antigens shared by malignant cells in the recipient. Approaches to exploiting this beneficial effect without the deleterious consequence of graft-versus-host disease in allogeneic hematopoietic cell recipients are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · cited 1×
“addition, it has been recently demonstrated that expression by tumor cells of human B7-H1, a member of the B7 family of costimulatory molecules, leads to induction of T-cell apoptosis and might, thereby, contribute to immune escape of these tumors [68].”
BackgroundIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · cited 1×
“[2-6].”
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380 · cited 1×
“Furthermore, it has been recently suggested that alloreactive NK cells might be critically involved in mediating graft-versus-leukemia (GVL) effects in the setting of MHC haploidentical hematopoietic stem-cell transplantation [15].”
BackgroundIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Graft-versus-leukemia reactions after bone marrow transplantation
Horowitz, M., Gale, R., Sondel, P., Goldman, J., Kersey, J., Kolb, H., Rimm, A., Ringden, O., Rozman, C., & Speck, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,774
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Cited by
Consensus statement on the pathology of IgG4-related disease
Deshpande, V., Zen, Y., Chan, J. K., Yi, E. E., Sato, Y., Yoshino, T., Klöppel, G., Heathcote, J. G., Khosroshahi, A., Ferry, J. A., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.72 · Cited by 2,596
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966
“The tumor microenvironment and local cytokine milieu are often suppressive toward immune function and can actively induce immune cell anergy or death (5, 6).”
BackgroundHiraoka, N., Onozato, K., Kosuge, T., & Hirohashi, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0369 · Cited by 831
Mesenchymal stem cells avoid allogeneic rejection
Ryan, J. M., Barry, F. P., Murphy, J. M., & Mahon, B. P. (2005) · Journal of Inflammation · doi:10.1186/1476-9255-2-8 · Cited by 714
The therapeutic promise of the cancer stem cell concept
Frank, N. Y., Schatton, T., & Frank, M. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41004 · Cited by 636
Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E. R., Werner-Felmayer, G., Weiss, H. G., G√∂bel, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1966 · Cited by 614
“The concept that the host’s immunologic response towards the primary tumor may be related to the metastatic potential (2) is further proven by the fact that IDO expression significantly correlated with the frequency of metastases.”
BackgroundInterleukin-10 and the immune response against cancer: a counterpoint
Mocellin, S., Marincola, F. M., & Young, H. A. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0705358 · Cited by 402
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 342
Nishio, N., Diaconu, I., Liu, H., Cerullo, V., Caruana, I., Hoyos, V., Bouchier-Hayes, L., Savoldo, B., & Dotti, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0697 · Cited by 331
Civenni, G., Walter, A., Kobert, N., Mihic-Probst, D., Zipser, M., Belloni, B., Seifert, B., Moch, H., Dummer, R., van den Broek, M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3997 · Cited by 326
O'Day, S. J., Hamid, O., & Urba, W. J. (2007) · Cancer · doi:10.1002/cncr.23086 · Cited by 309
The immune system and cancer evasion strategies: therapeutic concepts
Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304
Bacteriolytic therapy can generate a potent immune response against experimental tumors
Agrawal, N., Bettegowda, C., Cheong, I., Geschwind, J.-F., Drake, C. G., Hipkiss, E. L., Tatsumi, M., Dang, L. H., Diaz, L. A., Pomper, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406242101 · Cited by 304
Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells
Schatton, T., Schütte, U., Frank, N. Y., Zhan, Q., Hoerning, A., Robles, S. C., Zhou, J., Hodi, F. S., Spagnoli, G. C., Murphy, G. F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1592 · Cited by 287
Tacken, P. J., de Vries, I. J. M., Gijzen, K., Joosten, B., Wu, D., Rother, R. P., Faas, S. J., Punt, C. J. A., Torensma, R., Adema, G. J., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0318 · Cited by 272
Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy
Lee, N., Zakka, L. R., Mihm, M. C., & Schatton, T. (2016) · Pathology · doi:10.1016/j.pathol.2015.12.006 · Cited by 250
Decreased Total Lymphocyte Counts in Pancreatic Cancer: An Index of Adverse Outcome
Fogar, P., Sperti, C., Basso, D., Sanzari, M. C., Greco, E., Davoli, C., Navaglia, F., Zambon, C.-F., Pasquali, C., Venza, E., et al. (2006) · Pancreas · doi:10.1097/01.mpa.0000188305.90290.50 · Cited by 260
Chen, X., Lin, X., Zhao, J., Shi, W., Zhang, H., Wang, Y., Kan, B., Du, L., Wang, B., Wei, Y., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.3 · Cited by 173
Vahidian, F., Duijf, P. H. G., Safarzadeh, E., Derakhshani, A., Baghbanzadeh, A., & Baradaran, B. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.004 · Cited by 75
Metadata
- Authors
- Mapara, M. Y., & Sykes, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-03-15
- Volume
- 22
- Issue
- 6
- Pages
- 1136-1151
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2131774025
- Cited by
- 325
- References
- 175
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.